Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHanna L. ZiegerCentre National de la Recherche ScientifiquePBPeter BorchmannDüsseldorf University HospitalRJRon D. JachimowiczMax Planck Society

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved responses in large B-cell lymphoma with glofitamab bridging before CAR-T cell therapy, suggesting it's a viable strategy.

Key Points

  • To analyze the effectiveness and safety of glofitamab as a bridging therapy prior to CAR-T cell therapy in large B-cell lymphoma patients.
  • Conducted a retrospective analysis of patients undergoing glofitamab bridging versus conventional treatments prior to CAR-T therapy.
  • Response assessed using Lugano criteria and metabolic tumor volume measurements before and after CAR-T infusion.
  • Measured glofitamab levels and conducted CAR-T cell immunophenotyping through flow cytometry.
  • 69% response rate in glofitamab patients compared to 51% in conventional treatment group.
  • Median metabolic tumor volume reduction was 99% for glofitamab versus 81% for conventional bridging.
  • 60% of glofitamab patients achieved complete remission at three months post-CAR-T therapy.

Cite This Study

Zieger et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df6ahttps://doi.org/10.1182/blood-2025-3734
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  2. 2Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort2026